2023
Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk
Frumm S, Kim H, Kelkar A, Ho V, Gooptu M, Gibson C, Koreth J, Shapiro R, Romee R, Nikiforow S, Antin J, Soiffer R, Rolles B, Shimony S, Bewersdorf J, Kewan T, Alhajahjeh A, Luskin M, Garcia J, Chen E, Lane A, Wadleigh M, Winer E, Stone R, DeAngelo D, Zeidan A, Lindsley C, Cutler C, Stahl M. Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk. Blood 2023, 142: 3618. DOI: 10.1182/blood-2023-185220.Peer-Reviewed Original ResearchHematopoietic stem cell transplantBlood count recoveryPost-HCT outcomesComplete remissionTime of diagnosisMyelodysplastic syndromeOverall survivalHigh riskLower riskAgent therapyCount recoveryMolecular riskInternational Working Group response criteriaShorter median overall survivalResponse criteriaDana-Farber Cancer InstituteHCT comorbidity indexImportant prognostic impactTAC/sirolimusHost disease (GVHD) prophylaxisMedian overall survivalProgression-free survivalStem cell transplantBone marrow biopsyFuture prospective studies
2012
Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update
Holkova B, Bose P, Tombes M, Shrader E, Wan W, Weir-Wiggins C, Stoddert E, Sankala H, Kmieciak M, Roberts J, Garcia-Manero G, Grant S. Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update. Blood 2012, 120: 3588. DOI: 10.1182/blood.v120.21.3588.3588.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationStem cell transplantationAcute myeloid leukemiaRefractory acute leukemiaDose level 5Myelodysplastic syndromeStable diseaseCycles of treatmentPartial responseComplete responseAcute leukemiaChronic myelogenous leukemiaCML-BCAdverse eventsI trialMyelogenous leukemiaDay 1Allogeneic hematopoietic stem cell transplantationIncomplete blood count recoveryTreatment-related adverse eventsPrimary acute myeloid leukemiaAcute leukemia refractoryBlood count recoveryDose level 4Second partial response
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply